We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

Factors Associated With Maintenance of Antibody Responses to Influenza Vaccine in Older, Community-Dwelling Adults

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02401893
Recruitment Status : Completed
First Posted : March 30, 2015
Last Update Posted : March 30, 2015
Centers for Disease Control and Prevention
Marshfield Clinic Research Foundation
Information provided by (Responsible Party):
Keipp Talbot, Vanderbilt University

Brief Summary:
Little is known about factors associated with maintenance of hemagglutinin inhibition (HAI) antibodies after influenza vaccination in older adults so the investigators enrolled adults ≥50 years.

Condition or disease Intervention/treatment
Aging Biological: Influenza Vaccine

Show Show detailed description

Layout table for study information
Study Type : Observational
Actual Enrollment : 510 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: Factors Associated With Maintenance of Antibody Responses to Influenza Vaccine in Older, Community-Dwelling Adults
Study Start Date : September 2009
Actual Primary Completion Date : July 2010
Actual Study Completion Date : January 2014

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Flu Flu Shot Vaccines

Intervention Details:
  • Biological: Influenza Vaccine
    Everyone immunized as recommended by current guidelines

Primary Outcome Measures :
  1. Maintenance of Immune Response using Hemagglutinin inhibition titers [ Time Frame: 1 year ]

Biospecimen Retention:   Samples With DNA
serum samples were collected

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   50 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population
Subjects were enrolled at Vanderbilt University Medical Center and Marshfield Clinic Research Foundation during September and October 2009. Subjects were eligible for recruitment if they were ≥50 years of age and had no previous allergy or reaction to influenza vaccination.

Inclusion Criteria:

  • Age >=50 years

Exclusion Criteria:

  • Prior vaccine allergy or history of guillain barre
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Keipp Talbot, Assistant Professor, Vanderbilt University
ClinicalTrials.gov Identifier: NCT02401893    
Other Study ID Numbers: Serum 2009
First Posted: March 30, 2015    Key Record Dates
Last Update Posted: March 30, 2015
Last Verified: March 2015
Keywords provided by Keipp Talbot, Vanderbilt University:
influenza vaccine
immune responses
Additional relevant MeSH terms:
Layout table for MeSH terms
Influenza, Human
Respiratory Tract Infections
Orthomyxoviridae Infections
RNA Virus Infections
Virus Diseases
Respiratory Tract Diseases